FDA Approval Alert: The Need-to-Know | Lutetium Lu 177 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

In March 2025, the FDA expanded lutetium Lu 177 vipivotide tetraxetan’s indication to include adult patients with prostate-specific membrane antigen (PSMA)–positive, metastatic castration-resistant prostate cancer who received prior androgen receptor pathway inhibitor therapy and are appropriate to delay taxane-based chemotherapy.

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC
Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC
Article
Apr 18, 2025 2:00 PM
Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.
Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval
Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval
Article
Apr 17, 2025 6:00 PM
After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.
177Lu Marks Practice-Changing Approval in Metastatic CRPC
177Lu Marks Practice-Changing Approval in Metastatic CRPC
Video
Apr 16, 2025 10:00 PM
Steven Finkelstein, MD, DABR, FACRO, spoke about the impact of the approval of 177Lu for patients with PSMA-positive mCRPC.
Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.
FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC
Article
Mar 28, 2025 4:59 PM
Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.